Expertise in
15
conditions

Dr. Amol R. Rao

Oncology
OC Blood & Cancer Care
18111 Brookhurst St Ste 6100, 
Fountain Valley, CA 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
OC Blood & Cancer Care
18111 Brookhurst St Ste 6100, 
Fountain Valley, CA 

Overview

Amol Rao is an Oncologist practicing medicine in Fountain Valley, California.

Dr. Rao is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Colorectal Cancer.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 4 clinical trials. Dr. Rao is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Memorialcare Orange Coast Medical Center
Memorialcare Saddleback Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

OC Blood & Cancer Care
18111 Brookhurst St Ste 6100, Fountain Valley, CA 92708

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
View 3 Less Clinical Trials

2 Total Publications

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
Journal: Cancer
Published: March 16, 2017
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

City Of Hope Orange County Lennar Foundation Cancer Center

Irvine, CA 
 (12.9 miles away)
844-975-4048
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanya Siddiqi is an Oncologist practicing medicine in Irvine, California. Dr. Siddiqi is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Expertise in
19
conditions
Dr. Krishnansu S. Tewari
Oncology | Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Krishnansu S. Tewari
Oncology | Obstetrics and Gynecology
Referral may be required
Before you request

UC Irvine Medical Center

101 The City Drive South, Building 29, 
Orange, CA 
 (6.4 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Krishnansu Tewari is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Orange, California. Dr. Tewari is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy. Dr. Tewari is board certified in American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology - Gynecologic Oncology. Dr. Tewari is currently accepting new patients.

Expertise in
29
conditions
Dr. Jaime Landman
Oncology | Urology
Expertise in
29
conditions
Dr. Jaime Landman
Oncology | Urology
Referral may be required

UCI Health Newport - Birch Street

20350 Southwest Birch Street, Suite 210, 
Newport Beach, CA 
 (6.8 miles away)
714-456-7005
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Dr. Jaime Landman, director of the UCI HealthCenter for Urological Care, is an internationally recognized urologist and expert in diseases and conditions of the kidneys, including kidney stones and benign and malignant tumors. He is experienced in all forms of minimally invasive kidney surgery, including robot-assisted surgery and percutaneous cryoablation.Landman, who founded the UCI HealthAblative Oncology Center,has performed thousands of advanced minimally invasive kidney procedures. He is dedicated to improving the techniques and technology associated with minimally invasive surgery.The author of more than 185 peer-reviewed articles and more than 60 book chapters, Landman has lectured around the world on the subject of minimally invasive urology. His research interests are in kidney cancer outcomes, kidney ablation and kidney imaging technologies, as well as preserving kidney function.His research efforts have helped define many of the minimally invasive kidney procedures performed today, earning him the 2005 Arthur Smith prize for creativity and dynamic innovation at the World Congress of Endourology. His clinical interests include all aspects of minimally invasive urologic oncology, with special emphasis on kidney cancer and kidney stone disease. Dr. Landman is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Kidney Stones, Renal Cell Carcinoma (RCC), Ureterocele, Lithotripsy, and Nephrectomy. Dr. Landman is board certified in American Board Of Urology - Urology.

Frequently Asked Questions about Dr. Amol R. Rao

How do I make an appointment with Dr. Amol R. Rao?

You can book an appointment with Dr. Amol R. Rao by calling their office at 949-652-7871. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amol R. Rao a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amol R. Rao is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amol R. Rao specialize in?

While Dr. Amol R. Rao is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Amol R. Rao participate in research or clinical trials?

Yes. Dr. Amol R. Rao has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Amol R. Rao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amol R. Rao accept my insurance?

Dr. Amol R. Rao accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 949-652-7871 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rao's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 74 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile